MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

Yahoo Finance Published Updated Economy
Sign in to save

Why it matters

MediciNova has enrolled 100 patients in the SEANOBI study, a 50% milestone towards the planned 200 patients, evaluating MN-166 (ibudilast) in ALS patients through an expanded-access-program.

Article tone

Neutral How the article is written, as reported by the source.

Expected market reaction

Bullish Confidence 85% How confidence is read Horizon: Short term Impact: Moderate

Market impact analysis based on bullish sentiment with 85% confidence.

Evidence trail

Evidence
Source Yahoo Finance
Claim MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
AI inference Bullish · 85%
Generated 2026-01-29 23:00

AI provenance

Analysed by Llama 3.1 8B Instant (Groq) Methodology v1.0 Generated
Technical identifiers
Provider tag
groq-llama-3.1-8b-instant
Analysis version
groq-llama-3.1-8b-instant
Article id
39216

Original source

LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the end of January 2026, 12 sites in the US are activated and 100 patients have been enrolled in the SEANOBI study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS; NCT 06743776) representing 50% of the planned 200-en

Read the full article on Yahoo Finance

Original article published by Yahoo Finance on January 30, 2026. Analysis and insights provided by AnalystMarkets AI.

Related coverage